Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors.

Primary tabs

field_vote: 
Average: 5 (1 vote)
References: 
Publication type: 
Therapeutic Substance(s): 
Cancer Metastasis Rev. 2011 Mar;30 Suppl 1:19-26.

Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors.

Source

Medical Oncology Department, Beaujon University Hospital, INSERM U728, APHP, Paris 7 University, 100 bd du Général Leclerc, 92880, Clichy, France. eric.raymond@bjn.aphp.fr

Abstract

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) show limited sensitivity to cytotoxic agents, requiring the search for novel therapies. Recently, data from a phase III trial demonstrated that sunitinib produces a clinically significant improvement in progression-free survival in patients with unresectable, advanced, or metastatic GEP-NETs. Based on this finding, sunitinib became the first targeted drug approved for the treatment of GEP-NETs, paving the way for the approval of other anticancer agents in this drug-orphan disease. To date, results of trials involving other multitargeted tyrosine kinase inhibitors, such as sorafenib, the monoclonal antibody bevacizumab, and insulin-like growth factor 1 receptor inhibitors, have also shown promising results, and some are already being studied in phase III trials. This review updates the results of ongoing trials using inhibitors of growth factors and tyrosine kinase receptors involved in the carcinogenesis of GEP-NETs.

PMID:
21308478